XML 60 R39.htm IDEA: XBRL DOCUMENT v3.25.4

Segment Reporting (Tables)

12 Months Ended

Oct. 31, 2025

Segment Reporting [Abstract]

Summary of Significant Segment Expenses

The following table summarizes significant segment expenses, other segment items and the measure of segment net loss of the Company's reportable segment for the years ended October 31, 2025 and 2024:

	Year Ended October 31,
	2025				2024
Research and development expenses:
Chemistry, Manufacturing and Controls(1)	$	49,578			$	11,994
Clinical operations(2)		17,915				11,036
Other research and development expenses(3)		7,052				4,598
Personnel-related expenses, excluding stock-based compensation		16,653				8,893
Stock based compensation		3,282				1,794
Total research and development expenses	$	94,480			$	38,315
General and administrative expenses:
Personnel-related expenses, excluding stock-based compensation		10,850				8,501
Stock based compensation		6,364				3,530
Other general and administrative expenses(4)		11,471				11,951
Total general and administrative expenses		28,685				23,982
Other segment items(5)		(5,863	)			(7,155	)
Net loss	$	117,302			$	55,142

(1) External expenses associated with clinical manufacturing of the Company's lead compound, detalimogene.

(2) External and internal expenses associated with clinical operations related to research and development of the Company's lead compound, detalimogene.

(3) Represents research and development expenses associated with preclinical, medical affairs, regulatory, quality, program management and facility related costs.

(4) Represents general and administrative costs associated with external legal fees, facilities, professional fees, and other overhead costs.

(5) For the year ended October 31, 2025, other segment items consist of $9.4 million of interest income, $3.0 of interest expense, and $0.6 million of other expense, net. For the year ended October 31, 2024, other segment items consists of $10.4 million of interest income, $2.8 million of interest expense, $0.4 million gain on extinguishment of debt, and $0.1 million other expense, net. Interest income consists of interest income earned on cash equivalents and marketable securities. Interest expense consists of interest expense on our term loan. Other (income) expense, net primarily consists of realized and unrealized gains and losses.

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration